OakChart

4D Molecular Therapeutics Inc

FDMTHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 7:18 AM ET

12.40-0.06 (-0.48%)
2026-11-11 14:22 CET
Market cap
688.34 USD m
Revenue, TTM
92.01 USD m
Net income, TTM
-179.18 USD m
Free cash flow, TTM
-155.97 USD m
EPS diluted, TTM
-2.72
P/E
-
Compare

Price

FDMT against its 20, 50 and 200-day averages
2050200miss
8.0010.0012.0014.0016.001.7M3.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FDMTclose 12.4020-day 12.1450-day 13.23200-day 11.0412.40

26.8% under 16.93 on 19 Aug 2026. Last 15 sessions, 26.7% high to low

Profile

FDMT
52-week range, 55% of the way up
6.9616.93

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. The company combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine creates a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

IndexRUT
Employees196
IPODec 11, 2020
Beta2.90
ATR, 14d0.86
Rel volume0.00
Short float21.59%
Insider own8.62%
Inst own99.90%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap685.03M
Enterprise Value362.92M
Income-179.18M
Sales92.01M
Book/sh7.38
Cash/sh6.54
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees196
IPODec 11, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S7.45
P/B1.68
P/C1.90
P/FCF-
EV/EBITDA-
EV/Sales3.94
Quick Ratio8.03
Current Ratio8.03
Debt/Eq0.10
LT Debt/Eq0.08
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.72
EPS next Y-4.09
EPS next Q-1.05
EPS this Y-71.53%
EPS next Y1.37%
EPS next 5Y-15.85%
EPS past 3/5Y10.05% -2.62%
Sales past 3/5Y200.86% 44.32%
EPS Y/Y TTM26.59%
Sales Y/Y TTM278712.12%
EPS Q/Q-6.20%
Sales Q/Q25106.67%
EarningsAug 13 AMC
EPS/Sales Surpr.-2.29% 4.45%

Ownership

Insider Own8.62%
Insider Trans-8.05%
Inst Own99.90%
Inst Trans17.18%
ROA-37.09%
ROE-43.25%
ROIC-40.58%
Gross Margin91.17%
Oper. Margin-214.24%
Profit Margin-194.74%
SMA202.18%
SMA50-6.30%
SMA20012.32%
Trades-

Technical

Shs Outstand55.21M
Shs Float50.48M
Short Float21.59%
Short Ratio10.41
Short Interest10.90M
52W High16.93 -26.76%
52W Low6.96 78.16%
Volatility7.53% 7.79%
ATR (14)0.86
RSI (14)49.63
Beta2.90
Rel Volume0.00
Avg Volume1.05M
Volume26

Performance

Perf Week0.98%
Perf Month0.32%
Perf Quarter6.44%
Perf Half Y18.66%
Perf YTD65.33%
Perf Year14.81%
Perf 3Y12.22%
Perf 5Y-49.94%
Perf 10Y-
Recom1.25
Target Price28.09
Prev Close12.46
Price12.40
Change %-0.48%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 14, 2026UpgradeCCantor FitzgeraldNeutral → Overweight$20+61.3%
Jul 31, 2026InitiatedRB. Riley SecuritiesBuy$37+198.4%
Jan 28, 2026ResumedBBarclaysOverweight$33+166.1%
Nov 07, 2025UpgradeMMorgan StanleyUnderweight → Equal-Weight
Jan 13, 2025DowngradeBBMO Capital MarketsOutperform → Market Perform$40 → $15+21.0%
Nov 21, 2024InitiatedMMorgan StanleyUnderweight$8-35.5%
Sep 23, 2024DowngradeCCantor FitzgeraldOverweight → Neutral
Apr 15, 2024InitiatedBBarclaysOverweight$459+3,601.6%
Apr 15, 2024InitiatedBBarclaysOverweight$45+262.9%
Feb 07, 2024ResumedGGoldmanBuy$81+553.2%

Peers

Mkt cap
TickerCompanyMkt cap
RGNXRegenxbio Inc523.03M
OCULOcular Therapeutix Inc1.52B
EYPTEyePoint Inc35.18M
KODKodiak Sciences Inc6.79B
OCGNOcugen Inc330.82M
REGNRegeneron Pharmaceuticals Inc92.78B
QUREuniQure NV1.60B
SANASana Biotechnology Inc734.10M
KRYSKrystal Biotech Inc9.07B
ABBVAbbvie Inc512.86B

Insider trading

latest 14 of 44
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bizily ScottChief Legal OfficerOct 16 '26Option Exercise4.141,6356,76910,252Oct 20 04:56 PM
Bizily ScottChief Legal OfficerOct 16 '26Sale12.841,63520,9938,617Oct 20 04:56 PM
Kirn DavidSee RemarksOct 05 '26Sale12.9258,333753,937709,153Oct 07 05:11 PM
David KirnOfficerOct 05 '26Proposed Sale12.9258,333753,662Oct 05 06:23 PM
Bizily ScottChief Legal OfficerSep 16 '26Option Exercise4.141,6356,76910,252Sep 22 06:43 PM
Bizily ScottChief Legal OfficerSep 16 '26Sale13.651,63522,3188,617Sep 22 06:43 PM
Kirn DavidSee RemarksSep 14 '26Sale13.9058,333811,004767,486Sep 16 05:13 PM
David KirnOfficerSep 14 '26Proposed Sale13.7658,333802,662Sep 14 06:00 PM
Bizily ScottChief Legal OfficerSep 01 '26Option Exercise6.495843,7909,201Sep 03 06:55 PM
Bizily ScottChief Legal OfficerSep 01 '26Sale14.005848,1768,617Sep 03 06:55 PM
Kirn DavidSee RemarksAug 19 '26Option Exercise4.1450,000207,000894,895Aug 21 04:06 PM
Kirn DavidSee RemarksAug 19 '26Sale15.7569,0761,088,273825,819Aug 21 04:06 PM
David KirnOfficerAug 19 '26Proposed Sale16.7669,0761,157,714Aug 19 06:28 PM
Bizily ScottChief Legal OfficerAug 13 '26Option Exercise4.141,6356,76910,252Aug 17 05:34 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
XBIState Street SPDR S&P Biotech ETFAUM: 10.53B
IWMiShares Russell 2000 Index FundAUM: 78.30B
VXFVanguard Extended Market Index ETFAUM: 30.61B
IWNiShares Russell 2000 Value ETFAUM: 14.17B
IBBiShares Biotechnology ETFAUM: 11.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.57B
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.49B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.85B

News

latest 14 of 206
  • 4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.10%
  • 4DMT Announces New Employment Inducement Grants (GlobeNewswire) -5.67%
  • 4DMT to Host Investor Day on October 21, 2026 (GlobeNewswire) -5.49%
  • This is the top biotech stock pick from B Riley Securities (Investing.com)
  • OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs (Stocktwits)
  • Loading…
  • 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME (GlobeNewswire)
  • 4DMT Announces New Employment Inducement Grants (GlobeNewswire)
  • 4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • OCUL, FDMT Stock Clock Best Day In Weeks After EyePoints Trial Setback Heres Why (Stocktwits) +19.32%
  • 4DMT Announces New Employment Inducement Grants (GlobeNewswire)
  • 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
  • Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls (The Fly)
  • 10 Stock Picks to Celebrate 45 Years of Schaeffer's (Schaeffer's Research)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-1.040-1.017-1.0403.783.629
2026Q12026-05-07-1.010-0.996-1.0103.052.599
2025Q42026-03-180.430-0.5280.33785.1027.0010
2025Q32025-11-10-1.010-0.983-1.0130.090.2910
2025Q22025-08-11-0.980-0.727-0.9770.020.3911
2025Q12025-05-08-0.860-0.871-0.8610.010.4610
2024Q42025-02-28-0.890-0.836-1.0850.011.4211
2024Q32024-11-13-0.790-0.676-0.7890.001.6210
2024Q22024-08-08-0.630-0.684-0.6320.011.2710
2024Q12024-05-09-0.660-0.741-0.6580.011.4510
2023Q42024-02-29-0.690-0.726-0.820-0.022.4010
2023Q32023-11-09-0.240-0.613-0.24320.208.0710
2023Q22023-08-09-0.770-0.784-0.7730.240.858
2023Q12023-05-10-0.880-0.893-0.8770.301.296
2022Q42023-03-15-0.840-0.786-0.8431.220.877
2022Q32022-11-09-0.790-0.844-0.7930.500.385

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-6.973-2.637-2.12513.8115.21
2021FY-2.570-2.783-2.57218.0418.83
2022FY-3.320-3.173-3.3233.102.63
2023FY-2.580-2.607-2.57720.7222.61
2024FY-2.980-2.909-2.9820.041.28
2025FY-2.420-3.259-2.42085.2133.54
2026FY--4.151--13.26
2027FY--4.094--18.34
2028FY--3.763--45.79
2029FY--2.875--195.01
2030FY--1.263--409.39

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-286014.133.205.60
2026Q3S2026-10-216324.133.205.60
2026Q3S2026-10-057323.540.005.60
2026Q3S2026-10-026324.133.205.60
2026Q3S2026-08-165314.163.205.60
2026Q3S2026-08-146314.213.205.60
2026Q3S2026-08-136103.740.027.50
2026Q3S2026-07-246003.700.027.50
2026Q3S2026-07-225003.800.027.50
2026Q3S2026-06-276123.170.007.50
2026Q3S2026-06-027122.720.007.50
2026Q3S2026-05-087132.720.007.50
2026Q3S2026-04-136022.590.008.00
2026Q3S2026-03-195023.110.008.00

Estimate history

EPS, annual-0.451-0.384-1.861-2.125-2.572-3.323-2.577-2.982-2.419-2.7248
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.632-0.789-1.085-0.861-0.977-1.0130.337-1.01-1.038
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual5.7914.136.98613.61218.0383.12920.7230.03785.20992.01
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0050.0030.0010.0140.0150.0985.093.0473.781
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual24.88424.88426.49426.68232.22532.62743.07545.79457.60855.214
Period201720182019202020212022202320242025MRQ
Shares, quarterly51.91451.99745.79446.32546.746.77157.60852.27255.214
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue92.0185.210.0420.723.1318.0413.616.9914.13
Cost of Goods Sold Incl. D&A8.137.626.715.753.883.02---
Gross Profit83.8877.58-6.6714.97-0.7515.02---
Selling, General and Administrative Excl. Other281.00237.13181.17127.84109.2886.3568.8351.6123.83
Research and Development240.31195.70141.3097.1080.2561.3653.0438.7218.36
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-197.12-159.55-187.84-112.87-110.03-71.33-56.66-45.63-10.40
Interest Expense-0.000.000.000.000.000.000.000.00
Unusual Expense--0.050.040.16-0.00-0.09-0.025.10-0.01
Net Income Before Taxes-179.18-140.11-160.87-100.84-107.49-71.32-56.69-49.31-9.55
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-179.18-140.11-160.87-100.84-107.49-71.32-56.69-49.31-9.55
Net Income From Continuing Operations-179.18-140.11-160.87-100.84-107.49-71.32-56.69-49.31-9.55
Net Income-179.18-140.11-160.87-100.84-107.49-71.32-56.69-49.31-9.55
EPS (Recurring)-2.55-2.42-2.98-2.57-3.32-2.57-2.13-1.73-0.38
EPS (Basic, Before Extraordinaries)-2.72-2.42-2.98-2.58-3.32-2.57-2.12-1.86-0.38
EPS (Diluted)-2.72-2.42-2.98-2.58-3.32-2.57-2.12-1.86-0.38
EBITDA-188.99-151.92-181.14-107.12-106.15-68.31-55.22-44.62-9.70
Non-Operating Income (Expense)17.9519.3927.0112.192.54-0.08-0.051.420.83
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense20.4122.0226.1219.6617.1213.804.983.541.38
Price To Sales Ratio10.165.108,120.7238.26229.6333.7381.25--
Gross Margin91.1791.05-18,021.6272.26-24.0083.26---
Operating Margin-214.24-187.24-507,678.38-544.65-3,516.52-395.46-416.28-653.12-73.60
Net Margin-194.74-164.43-434,778.38-486.59-3,435.41-395.37-416.49-705.78-67.59
Shares Outstanding55.2157.6145.7943.0832.6332.2226.6826.4924.88
Market Capitalization688.34688.34257.49866.19719.44705.131,098.161,103.20-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue3.783.0585.090.090.010.010.000.00
Cost of Goods Sold Incl. D&A2.092.061.982.001.891.751.781.70
Gross Profit1.690.9983.11-1.91-1.87-1.74-1.78-1.70
Selling, General and Administrative Excl. Other78.7274.6168.3959.2757.5851.8854.3349.43
Research and Development68.2864.9857.6149.4447.9540.7043.0938.48
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-77.03-73.6214.71-61.19-59.46-53.62-56.12-51.13
Interest Expense-0.000.000.000.000.000.000.00
Unusual Expense-0.01-0.010.010.01-0.090.010.01
Net Income Before Taxes-72.94-68.7619.40-56.88-54.66-47.97-49.67-43.84
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-72.94-68.7619.40-56.88-54.66-47.97-49.67-43.84
Net Income From Continuing Operations-72.94-68.7619.40-56.88-54.66-47.97-49.67-43.84
Net Income-72.94-68.7619.40-56.88-54.66-47.97-49.67-43.84
EPS (Recurring)-1.04-1.010.34-1.01-0.98-0.86-1.08-0.79
EPS (Basic, Before Extraordinaries)-1.04-1.010.34-1.01-0.98-0.86-1.08-0.79
EPS (Diluted)-1.04-1.010.34-1.01-0.98-0.86-1.08-0.79
EBITDA-74.94-71.5616.70-59.18-57.57-51.87-54.33-49.43
Non-Operating Income (Expense)4.084.864.704.324.815.566.467.30
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.884.455.554.524.966.997.586.49
Price To Sales Ratio10.167.185.074,064.486,287.567,828.406,893.84-
Gross Margin44.7532.5697.67-2,125.56-12,486.67-12,428.57-178,300.00-56,666.67
Operating Margin-2,037.16-2,416.1517.29-67,983.33-396,373.33-383,007.14--
Net Margin-1,929.01-2,256.6522.80-63,195.56-364,386.67-342,657.14--
Shares Outstanding55.2152.2757.6146.7746.7046.3245.7952.00
Market Capitalization688.34475.29428.51405.84171.86149.56257.49561.79

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments402.65424.88288.23213.55247.78276.7349.6591.7623.85
Short Term Receivables0.000.000.000.700.051.490.981.120.32
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets10.4810.058.366.268.464.441.881.180.33
Total Current Assets413.13434.93296.59220.51256.28282.6652.5194.0724.50
Net Property, Plant & Equipment33.0140.6131.6635.3528.955.075.052.472.72
Total Investments and Advances111.3880.5810.954.9167.650.000.000.000.00
Other Assets9.194.260.681.080.600.600.680.430.10
Total Assets566.71560.38339.89261.85353.49288.3358.2396.9727.32
Short Term Debt Incl. Current Port. of LT Debt5.595.643.152.651.230.000.000.000.00
Accounts Payable11.164.393.523.324.761.791.740.950.46
Other Current Liabilities27.2319.1312.299.7510.3414.9611.217.105.45
Total Current Liabilities43.9829.1518.9515.7316.3416.7412.968.055.91
Long Term Debt15.8218.9711.5213.4715.220.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities1.241.661.591.312.8315.2015.2713.5222.49
Total Liabilities61.0549.7832.0630.5134.3831.9428.2221.5828.40
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00102.98102.9818.51
Common Equity505.66510.61307.83231.34319.11256.39-72.97-27.59-19.59
Total Shareholders Equity505.66510.61307.83231.34319.11256.3930.0175.39-1.08
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity505.66510.61307.83231.34319.11256.3930.0175.39-1.08
Total Liabilities & Stockholders Equity566.71560.38339.89261.85353.49288.3358.2396.9727.32
Book Value Per Share8.7811.157.157.099.909.61-2.75-1.11-0.79
Tangible Book Value Per Share8.7811.157.157.099.909.61-2.75-1.11-0.79
Full-Time Employees19622714714012483---
Price to Book Ratio1.690.522.622.862.22-15.05-15.12--
Return on Assets-24.86-35.74-33.52-34.94-22.22-32.72-63.54-15.37-
Return on Equity-27.57-39.31-37.40-39.06-24.78-39.59-93.56-25.71-
Return on Invested Capital-26.87-30.38-31.58-43.91-21.33-22.11-164.30-12.67-
Quick Ratio9.3914.9215.6514.0215.6916.884.0511.684.15
Current Ratio9.3914.9215.6514.0215.6916.884.0511.684.15

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-179.18-140.11-160.87-100.84-107.49-71.32-56.69-49.31-9.55
Depreciation8.137.626.715.753.883.021.441.000.70
Other Funds (Non Cash)16.0817.2319.0418.6718.2714.705.0511.331.38
Funds from Operations-154.97-115.25-135.12-76.42-85.35-53.60-50.20-36.97-7.47
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.106.170.540.63-1.34-15.53-0.710.26-8.78
Cash from Operating Activities-156.07-109.08-134.59-75.79-86.69-69.13-50.91-36.71-16.25
Capital Expenditures0.11-0.54-3.79-2.77-11.54-9.11-1.00-3.20-0.41
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-16.74-92.44-298.65118.49-5.51-163.570.000.000.00
Purchase of Investments-288.90-442.82-467.65-54.80-153.31-168.570.000.000.00
Sale Or Maturity of Investments272.15350.38169.00173.29147.805.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-16.64-92.97-302.44115.72-17.05-172.68-1.00-3.20-0.41
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock146.66112.96337.25156.833.08118.09-277.27-2.1984.58
Repurchase of Common Pref Stock0.000.000.000.000.000.00-278.130.000.00
Sale of Common Pref Stock146.66112.96337.25156.833.08118.090.86-2.1984.58
Proceedsfrom Stock Options143.90111.98332.67149.520.35114.730.86-2.1984.58
Issuance or Reduction of Debt, Net19.260.000.000.000.000.000.000.000.00
Change in Long Term Debt19.260.000.000.000.000.000.000.000.00
Issuance of Long Term Debt19.260.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities165.92112.96337.25156.833.08118.09278.98-2.1984.58
Net Change in Cash-6.79-89.09-99.77196.76-100.65-123.72227.07-42.1167.91
Free Cash Flow-155.97-109.62-138.37-78.56-98.22-78.24-51.91-39.91-16.67
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments361.33390.89402.65305.06293.23321.44
Short Term Receivables4.610.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets17.0114.4710.487.3110.0611.13
Total Current Assets382.96405.36413.13312.38303.29332.57
Net Property, Plant & Equipment28.9330.9433.0135.0637.1539.12
Total Investments and Advances69.3066.74111.3867.17123.81137.00
Other Assets11.449.869.199.389.397.04
Total Assets492.62512.90566.71423.98473.64515.73
Short Term Debt Incl. Current Port. of LT Debt5.375.495.595.705.725.68
Accounts Payable12.5214.6911.166.868.704.15
Other Current Liabilities29.7823.2327.2324.5520.2617.07
Total Current Liabilities47.6743.4043.9837.1134.6826.90
Long Term Debt33.8415.0515.8216.5717.3618.17
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities3.442.621.241.320.710.93
Total Liabilities84.9661.0761.0555.0052.7546.01
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity407.66451.84505.66368.98420.89469.72
Total Shareholders Equity407.66451.84505.66368.98420.89469.72
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity407.66451.84505.66368.98420.89469.72
Total Liabilities & Stockholders Equity492.62512.90566.71423.98473.64515.73
Book Value Per Share7.388.648.787.899.0110.14
Tangible Book Value Per Share7.388.648.787.899.0110.14
Full-Time Employees--196---
Price to Book Ratio1.691.060.950.960.370.29
Return on Assets-37.09-31.28-24.86-40.70-35.87-30.80
Return on Equity-43.25-34.92-27.57-45.38-38.87-32.97
Return on Invested Capital-16.52-14.733.72-14.75-12.47-9.83
Quick Ratio8.039.349.398.428.7512.36
Current Ratio8.039.349.398.428.7512.36

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-72.94-68.7619.40-56.88-54.66-47.97
Depreciation2.092.061.982.001.891.75
Other Funds (Non Cash)4.953.334.423.383.805.63
Funds from Operations-65.90-63.3725.80-51.50-48.97-40.59
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.10-4.752.755.005.59-7.17
Cash from Operating Activities-70.00-68.1228.55-46.50-43.38-47.76
Capital Expenditures-0.060.000.070.09-0.07-0.63
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.010.010.000.000.000.00
Purchase or Sale of Investments25.6168.88-128.9217.69-13.7932.58
Purchase of Investments-62.04-33.52-178.10-15.24-115.40-134.08
Sale Or Maturity of Investments87.65102.4049.1832.93101.62166.66
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities25.5468.89-128.8517.78-13.8531.95
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock23.0811.48111.980.120.860.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock23.0811.48111.980.120.860.00
Proceedsfrom Stock Options22.979.81111.120.000.860.00
Issuance or Reduction of Debt, Net19.260.000.000.000.000.00
Change in Long Term Debt19.260.000.000.000.000.00
Issuance of Long Term Debt19.260.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities42.3411.48111.980.120.860.00
Net Change in Cash-2.1212.2511.69-28.60-56.37-15.81
Free Cash Flow-70.05-68.1228.62-46.41-43.44-48.39

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 37.00K 2025: 85.21M
Japan2025: 85.00M
United States2024: 37.00K 2025: 209.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.59%10.9M50.5M1.00M
2026-10-1522.84%11.5M50.5M938.72K
2026-09-3022.29%11.2M50.4M902.38K
2026-09-1523.82%12.0M50.4M938.40K
2026-08-3124.10%12.1M50.1M957.52K
2026-08-1424.54%12.3M50.1M843.06K
2026-07-3125.62%12.0M47.0M857.17K
2026-07-1524.21%11.4M46.9M857.91K
2026-06-3028.38%13.3M46.9M851.20K
2026-06-1527.64%12.9M46.8M766.50K
2026-05-2926.14%12.2M46.6M758.48K
2026-05-1525.90%12.1M46.6M737.80K
2026-04-3025.74%12.0M46.6M757.83K
2026-04-1525.32%11.5M45.5M764.20K
2026-03-3123.88%10.9M45.5M787.67K
2026-03-1322.86%10.4M45.5M891.39K
2026-02-2722.29%10.1M45.5M898.71K
2026-02-1321.38%9.7M45.5M899.62K
2026-01-3019.99%9.3M46.4M951.56K
2026-01-1518.23%9.5M52.0M996.36K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call6.004.008.500.008.5140.000.000.905-0.0860.003
call7.003.007.500.007.1950.000.000.884-0.0830.004
call8.002.506.400.005.9150.000.000.859-0.0790.005
call9.001.505.700.005.5110.000.000.828-0.0740.005
call10.000.504.904.024.9521.000.000.787-0.0670.006
call11.000.104.900.005.6550.000.000.704-0.0730.007
call12.000.004.901.126.0641000.000.636-0.1320.008
call13.000.002.650.203.53777.000.000.611-0.1670.008
call14.000.001.400.202.4134.000.000.463-0.1000.008
call15.000.001.200.652.51618.000.000.405-0.1020.008
call16.000.004.900.002.7910.000.000.379-0.1090.008
call17.000.001.000.102.8211.000.000.331-0.1070.007
call18.000.004.900.203.02510.000.000.315-0.1100.007
call19.000.004.900.803.2361.000.000.303-0.1160.007
call20.000.004.900.003.4290.000.000.293-0.1210.007
call21.000.004.900.003.5920.000.000.284-0.1250.007
call22.000.004.900.003.7580.000.000.277-0.1300.007
put6.000.004.900.005.6430.000.00-0.106-0.1060.004
put7.000.004.900.004.7310.000.00-0.130-0.1020.004
put8.000.004.900.003.9630.000.00-0.157-0.0980.005
put9.000.004.900.003.2600.000.00-0.192-0.0910.006
put10.000.004.900.502.6292.000.00-0.236-0.0820.006
put11.000.000.650.702.05591.000.00-0.296-0.0730.007
put12.000.001.500.802.1681.000.00-0.364-0.1310.008
put13.000.104.900.005.7680.000.00-0.389-0.1660.008
put14.000.504.900.004.8560.000.00-0.537-0.0990.008
put15.000.504.900.003.9690.000.00-0.595-0.1000.008
put16.001.506.000.004.4040.000.00-0.620-0.1100.008
put17.002.507.000.004.6830.000.00-0.669-0.1050.007
put18.003.508.000.004.9360.000.00-0.684-0.1110.007
put19.004.509.000.005.1670.000.00-0.697-0.1170.007
put20.005.5010.000.005.3780.000.00-0.707-0.1220.007
put21.006.5011.000.005.5750.000.00-0.716-0.1270.007
put22.007.5012.000.005.7570.000.00-0.723-0.1310.007

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-09-288-KCurrent report2026-09-28SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-07-208-KCurrent report2026-07-18SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-10144Filing for proposed sale of securities under Rule 144.SEC
2026-07-09144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-298-KCurrent report2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-22SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000774.93K2
2026-0900841.50K3
2026-08001.53M5
2026-0700737.41K2
2026-06001.34M3
2026-050000
2026-040000
2026-03003.36K1
2026-020000
2026-010000
2025-120021.20K2
2025-110017.31K1

Institutional holders

Manager% owned
Jupiter Topco LLC10.99%
RA CAPITAL MANAGEMENT, L.P.9.66%
BlackRock, Inc.8.70%
GOLDMAN SACHS GROUP INC8.15%
Novo Holdings A/S6.22%
STATE STREET CORP5.57%
BVF INC/IL5.51%
T. Rowe Price Investment Management, Inc.4.81%
ADAGE CAPITAL PARTNERS GP, L.L.C.4.30%
Trails Edge Capital Partners, LP4.26%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.08%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.04%
iShares Russell 2000 ETF2.26%
Janus Henderson Global Life Sciences Fund1.51%
T. Rowe Price Small-Cap Stock Fund, Inc.1.30%
Fidelity Small Cap Index Fund0.96%
VANGUARD EXTENDED MARKET INDEX FUND0.88%
T. Rowe Price Small-Cap Value Fund, Inc.0.87%
iShares Russell 2000 Value ETF0.79%
Nuveen Quant Small Cap Equity Fund0.74%

OakChart. FDMT. Cached 15 minutes.